Albireo to Present Clinical Data on A4250 at The International Liver Congress™ 2018

Press Releases

<<  Back
Albireo to Present Clinical Data on A4250 at The International Liver Congress™ 2018

BOSTON, March 28, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that new data from its completed Phase 2 trial of lead product candidate A4250 in children with cholestatic liver disease and pruritus will be presented during a poster session at the European Association for the Study of the Liver (EASL) The International Liver Congress 2018, being held April 11-15, 2018, at the Paris Convention Center in Paris.

Details of the presentation are as follows:

Title: Correlation of autotaxin levels, serum bile acids, and pruritus in a multiple-dose, open-label, multinational study of the ileal bile acid transport inhibitor A4250
Abstract Number: 526
Poster Session: Rare liver diseases (including paediatric and genetic)
Date/Time:Saturday, April 14, 9 a.m. - 5 p.m. CEST
Location:Paris Convention Center, Pavilion 7, Hall 7.2
Presenter: Dr. Emmanuel Gonzalès, Associate Professor of Pediatric Hepatology and Liver Transplantation, University Hospitals of Paris-Sud, Bicetre, France

The International Liver Congress is the annual EASL meeting, which brings together more than 10,000 scientific and medical experts from around the world to learn about the latest in liver research. For more information about the conference, visit

About Albireo 
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. 

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit

Investor Contact:Hans Vitzthum, LifeSci Advisors, LLC., 212-915-2568                                       

Media Contact:Sarah Hall, 6 Degrees, 215-313-5638,

Source: Albireo Pharma, Inc.

Primary Logo

Source: Albireo Pharma, Inc.